Interestingly, patients with CLDN18-ARHGAP26/6 fusions tended to have a higher N stage (P = 2.2 × 10−7, Logistic regression test) and M stage (P = 0.003, Logistic regression test), but not T stage (P = 0.13, Logistic regression test), indicating this fusion may contribute to tumor metastasis rather than invasion. Here, ARHGAP26 is linked to neoplasm.